A retrospective analysis of clinical outcomes between hospitalized patients with COVID-19 who received famotidine or pantoprazole.

Background And Aim: There is limited research on the use of histamine-H2 receptor antagonists and proton pump inhibitors for treating COVID-19. We compare clinical outcomes between patients hospitalized with COVID-19 receiving famotidine or pantoprazole.

Methods: This retrospective study included 2184 patients (famotidine:  = 638, pantoprazole:  = 727, nonuse:  = 819) aged 18 years or older treated for COVID-19 from March 2020 to March 2021.